Navigation Links
Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data
Date:4/3/2011

NATICK, Mass. and NEW ORLEANS, April 3, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the next-generation ION™ Platinum Chromium (PtCr) Paclitaxel-Eluting Stent System (TAXUS® Element™) compared to the currently available TAXUS® Liberte® Paclitaxel-Eluting Stent System.  Results were presented at the American College of Cardiology Annual Scientific Sessions by Dean Kereiakes, M.D., Medical Director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati and Principal Investigator for the PERSEUS clinical program.

"Although the ION and TAXUS Liberte Stents employ the same drug and polymer, the ION Stent demonstrated significantly lower rates of major adverse cardiac events (MACE), target lesion failure (TLF) and myocardial infarction (MI) in this case-matched analysis of nearly 2,300 patients," said Dr. Kereiakes.  "This study demonstrates that alloy composition, stent design and strut thickness may influence angiographic and clinical outcomes following drug-eluting stent deployment."

The study compared pooled patient-level data from 2,298 patients enrolled in the PERSEUS (ION Stent) and TAXUS ATLAS (TAXUS Liberte Stent) trials.  Propensity score matching was performed to adjust for differences in patient and lesion characteristics between the groups, and clinical follow-up was conducted out to 12 months.  Propensity-matched results in 1,326 patients revealed that the ION Stent achieved significantly lower rates of MACE (7.5 percent vs. 12.0 percent, p=0.007) and TLF (5.5 percent vs. 8.5 percent, p=0.04) largely driven by a reduction in myocardial infarction (1.8 percent vs. 3.9 percent, p=0.
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
2. Boston Scientific Announces Its ACC 2011 Schedule
3. Boston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System
4. Boston Scientific to Webcast Analyst Event
5. Boston Scientific to Present at Barclays Capital 2011 Global Healthcare Conference
6. Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System
7. Unilife to Present at the 31st Annual Cowen Health Care Conference on Wednesday, March 9, 2011 in Boston
8. Boston Scientific Strengthens Structural Heart Product Portfolio By Completing Acquisition of Atritech
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
11. Boston Scientific Launches PROMUS® Element™ and TAXUS® Element™ Stent Systems in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  Beamz Interactive, Inc. (OTCQB: BZIC), ... today announced that it has signed an agreement ... supplier of innovative prosthetic, orthotic and assistive technology ... the agreement, RSL Steeper will promote and supply ... for use within UK residential care facilities through ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... 04, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc.'s lead drug ... the treatment of hot flashes associated with ... in the company's,double-blind, placebo- controlled, randomized Phase ... moderate to severe hot flashes,per week were ...
... analyses of progression-free survival in,the SPARC Phase ... risk of disease progression for patients receiving,satraplatin. ... well as presence or absence of pain., ... and GPC Biotech AG today announced the ...
Cached Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
(Date:12/19/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- A new ... -- moderate to severe hot flashes and night sweats ... bones. Hot flashes are common during menopause, affecting ... menopause also affect women after menopause, since they then ... "Our findings suggest women who exhibit moderate or ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Traveling through the ... measles virus to three others within a four-hour time ... a new report shows. "The exposures in this ... rather than an international terminal, highlighting the fact that ... Jared Vega, an infectious disease specialist at the U.S. ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 2014 A group of 127 scientists sent ... in reaction to a recent statement by the center that ... and derogated the efficacy of all brain exercises. , Signatories ... parts of the center’s statement critical of brain exercise companies ... also overstated its case, in a document it had entitled ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... in CT scanner technology have made perfusion computed tomography ... suspected stroke. Now, researchers at Mayo Clinic are working ... other CT images. Mayo Clinic medical physicist Cynthia McCollough, ... related to CT dose reduction at the 52nd Annual ...
... and Massachusetts believe the Earth has been getting warmer ... percent and 84 percent, respectively), and large majorities favor ... new public opinion research by Professor Jon Krosnick, a ... at Stanford University. Following up on a ...
... A major breakthrough in how to target and destroy ... been made by researchers at Wake Forest University Baptist ... to target and destroy Glioblastoma multiforme (GBM) cells without ... possibilities in cancer research previously not known to be ...
... found a new mechanism that explains how certain immune ... or pathological antibodies such as those present in autoimmune ... published online in the September issue of Nature ... Professor of Medicine at Mount Sinai School of Medicine, ...
... By Ellin Holohan HealthDay Reporter , TUESDAY, ... rising, their quality of life is falling, according to new ... healthy days per year that Americans lose due to obesity ... about 7.5 in 1993 to 17 in 2008. Researchers ...
... HealthDay Reporter , MONDAY, Aug. 2 (HealthDay News) ... A new two-year study suggests that it may not ... about eating and exercise, people lost about the same amount ... or a traditional low-fat diet. "In general, dieters should ...
Cached Medicine News:Health News:Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts 2Health News:New state surveys affirm Americans' support for government action on climate change 2Health News:New state surveys affirm Americans' support for government action on climate change 3Health News:Scientists develop 'designer protein,' opening new door in cancer research 2Health News:Scientists develop 'designer protein,' opening new door in cancer research 3Health News:New drug target for immune diseases discovered 2Health News:Weight Gain Eroding Americans' Quality of Life 2Health News:Weight Gain Eroding Americans' Quality of Life 3Health News:Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss 2Health News:Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss 3
... primer combinations in the PCR amplification. It ... primers whose sequence is completely complementary to ... the polymerase into PCR products. In contrast, ... the Biotest SSP Kit Systems, reliable typing ...
... constructed with built-in bags as in a suspension ... placed without contacting the ethylene glycol and without ... device ensures easy handling and maximum surface freezing ... that the relatively hot air under the lid ...
It includes 99 single plasma units. Model 8001 (8003), includes 11 roll-out drawers containing removable wire baskets....
... PillCam SB Capsule Endoscope is a ... the gastrointestinal tract. Natural peristalsis moves ... painlessly throughout the gastrointestinal tract, transmitting ... The procedure is ambulatory, allowing patients ...
Medicine Products: